Future vaccination strategies - PART 1

SCS

Future vaccination strategies - PART 1 SCS03

Auditorium 1 - Plenary Hall

Chairs

Florian KRAMMER

ESWI Board Member, Medical University of Vienna, Austria

Marios KOUTSAKOS

University of Melbourne, Australia

A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa

Daryl LEENational University of Singapore, Singapore
Development of a next-generation COVID-19 intranasal vaccine based on a multivalent NDV-HXP-S formulation.

Marta BOZA CUENCAIcahn School of Medicine at Mount Sinai, United States
Superior protection and prevention of transmission upon influenza infection by adjuvanted mucosal vaccination in the guinea pig influenza model.

To be confirmed
Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines

Anass ABBADIcahn Medical School at Mount Sinai, United States
The Additive Effect of Neuraminidase Inclusion in Influenza Vaccine Formulations using a Self-Amplifying RNA Platform

Giuseppe PALLADINOCSL, United States
Evaluation of a broadly protective influenza B virus vaccine based on mosaic hemagglutinin platforms in mice.

Irene GONZÁLEZ-DOMÍNGUEZIcahn School of Medicine at Mount Sinai, United States